StreetInsider.com News Articles

Form 4 VERU INC. For: Aug 13 Filed by: BARNETTE K GARY

Mon, 17 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260817/26938281.html

Form 4 VERU INC. For: Aug 13 Filed by: BARNETTE K GARY

Mon, 17 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260817/26938281.html

Form 10-Q VERU INC. For: Jun 30

Mon, 10 Aug 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260810/26895168.html

Form 10-Q VERU INC. For: Jun 30

Mon, 10 Aug 2026 08:52:00 -0400

si-local-file:///var/storage/secattach/20260810/26895168.html

Veru, Inc. (VERU) Tops Q3 EPS by 1c

Mon, 10 Aug 2026 08:13:28 -0400

Veru, Inc. (NASDAQ: VERU) reported Q3 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Veru, Inc. (VERU) click here.

Form 8-K VERU INC. For: Aug 10

Mon, 10 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26894082.html

Form 8-K VERU INC. For: Aug 10

Mon, 10 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26894082.html

Veru posts Q3 loss, reports full enrollment in obesity drug trial

Mon, 10 Aug 2026 06:30:26 -0400

Veru Inc. (NASDAQ: VERU) reported a net loss of $7.0 million, or $0.30 per share, for its fiscal third quarter ended June 30, 2026, compared with a net loss of $7.3 million, or $0.50 per share, in the same period a year earlier, according to a company press release.

Research and development expenses rose to $4.4 million from $3.0 million in the prior-year quarter, while general and administrative expenses declined to $3.4 million from $5.0 million. The operating loss from continuing operations widened slightly to $7.7 million from $7.5 million.

For the nine months ended June 30, 2026, net loss totaled $15.1

Veru posts Q3 loss, reports full enrollment in obesity drug trial

Mon, 10 Aug 2026 06:30:26 -0400

For the nine months ended June 30, 2026, net loss totaled $15.1

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Mon, 10 Aug 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –

-- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027--

-- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial --

-- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 --

-- Company to

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Mon, 10 Aug 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –

-- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027--

-- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial --

-- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 --

-- Company to

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Mon, 10 Aug 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –

-- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027--

-- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial --

-- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 --

-- Company to

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Mon, 10 Aug 2026 06:30:00 -0400

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –

-- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027--

-- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial --

-- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 --

-- Company to

Veru receives patent allowance for enobosarm and semaglutide combo

Tue, 04 Aug 2026 08:30:52 -0400

Veru Inc. (NASDAQ: VERU) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of use for its drug enobosarm in combination with semaglutide for weight loss purposes.

The allowed patent application is titled "Compositions Comprising Selective Androgen Receptor Modulator Compounds in Combination with Weight Loss Drugs and Uses Thereof for Quality Weight Loss." When issued, the patent is expected to provide protection until at least October 3, 2044, before any patent term adjustment or extension.

The allowed claims cover treatment regimens including concurrent use of enobosarm with semaglutide, adding

Veru receives patent allowance for enobosarm and semaglutide combo

Tue, 04 Aug 2026 08:30:52 -0400

Veru Inc. (NASDAQ: VERU) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of use for its drug enobosarm in combination with semaglutide for weight loss purposes.

The allowed patent application is titled "Compositions Comprising Selective Androgen Receptor Modulator Compounds in Combination with Weight Loss Drugs and Uses Thereof for Quality Weight Loss." When issued, the patent is expected to provide protection until at least October 3, 2044, before any patent term adjustment or extension.

The allowed claims cover treatment regimens including concurrent use of enobosarm with semaglutide, adding

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Tue, 04 Aug 2026 08:30:00 -0400

-- When issued U.S. patent protection until at least October 2044 --

-- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --

MIAMI, FL, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application titled

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Tue, 04 Aug 2026 08:30:00 -0400

-- When issued U.S. patent protection until at least October 2044 --

-- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --

MIAMI, FL, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application titled

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Tue, 04 Aug 2026 08:30:00 -0400

-- When issued U.S. patent protection until at least October 2044 --

-- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --

MIAMI, FL, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application titled

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

Tue, 04 Aug 2026 08:30:00 -0400

-- When issued U.S. patent protection until at least October 2044 --

-- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of other pending methods of use and formulation patent applications --

MIAMI, FL, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application titled

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Mon, 03 Aug 2026 08:30:00 -0400

MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Mon, 03 Aug 2026 08:30:00 -0400

MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Mon, 03 Aug 2026 08:30:00 -0400

MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Mon, 03 Aug 2026 08:30:00 -0400

MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Monday, August 10, 2026, at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and to provide a business update.

The audio webcast will be accessible under the Home page and Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Thu, 30 Jul 2026 08:30:00 -0400

MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Canaccord Genuity's 46th Annual Growth Conference, in Boston, Massachusetts, on August 12, 2026 at 2:00 pm – 2:25 pm Eastern Daylight Time.

A live webcast will be accessible through the Investors section of the Company’s website at www.verupharma.com. Following the

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

Thu, 30 Jul 2026 08:30:00 -0400

MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Canaccord Genuity's 46th Annual Growth Conference, in Boston, Massachusetts, on August 12, 2026 at 2:00 pm – 2:25 pm Eastern Daylight Time.

A live webcast will be accessible through the Investors section of the Company’s website at www.verupharma.com. Following the